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Abstract
Background: This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid 
(ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population-
-based cohort study in Taiwan. 
Methods: A newly diagnosed low-risk AF patient cohort were identified by using National Health 
Insurance Research Database (NHIRD) in Taiwan in 2008. The study cohort was observed with  
a follow-up of 2 years to  examine the onset of ischemic stroke (IS) (to 2010). The longitudinal data were 
analyzed by using generalized estimation equations (GEE). 
Results: A total of 8,065 newly-diagnosed low-risk AF patients were identified in 2008. 7.4% were 
prescribed with ASA and 4.6% were prescribed with warfarin. The GEE results showed that low-risk 
AF patients with hypertension who received warfarin were associated with a statistically significant 
58.4% reduction of IS risk (OR = 0.416, p = 0.024, 95% CI 0.194–0.891). Additionally, low-risk AF 
patients with hyperlipidemia who received warfarin were associated with a 69.3% reduction of IS risk 
(OR = 0.307, p = 0.044, 95% CI 0.097–0.969).
Conclusions: Warfarin is suggested to be prescribed in preventing IS for low-stroke-risk AF patients 
with hypertension and hyperlipidemia. (Cardiol J 2019; 26, 6: 704–710)
Key words: atrial fibrillation, acetylsalicylic acid, warfarin, ischemic stroke,  
hypertension, diabetes mellitus, hyperlipidemia
Introduction
The prevalence of atrial fibrillation (AF) is 
increasing in United States, European and Asian 
countries [1–3]. The incidence of AF was about 
1.5 per 1000 person-years in Taiwan [4]. In recent 
years, although many novel oral anticoagulants 
(NOACs) were proposed and have been demon-
strated significantly effective in stroke prevention, 
especially in high stroke-risk AF patients, for ex-
ample, rivaroxaban [5], dabigatran [6] and apixaban 
[7], but the NOACs were relatively more expensive 
compared to the two widely-used drugs: warfarin 
or acetylsalicylic acid (ASA). Consequently, war-
farin or ASA were considered to be prescribed for 
low-stroke-risk AF patients [8]. Although most 
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published studies aimed mainly to investigate the 
effectiveness of ASA or warfarin in preventing 
stroke events for moderate and high-stroke-risk 
AF patients [9], there remain relatively few stud-
ies investigating the effectiveness of preventing 
stroke events for low-stroke-risk AF patients. One 
large scale study conducted in the United States 
found that, among AF patients with high-stroke-
risk (CHADS2 score ≥ 2), 38.2% were treated with 
ASA alone, 61.8% were treated with warfarin or 
non-vitamin K antagonist oral anticoagulation [9], 
which indicated that prescribing ASA or warfarin is 
still very common for high-stroke-risk AF patients. 
However, prescribing warfarin or ASA to low-
stroke-risk AF patients for prevention of stroke is 
still debatable among clinicians and cardiovascular 
physicians [10–12], especially for those with meta-
bolic syndromes (including hypertension, diabetes 
mellitus [DM] and hyperlipidemia) [13]. However, 
prescribing ASA or warfarin, or combining uses of 
both drugs to AF patients may be of concern for 
increasing the risk of unexpected bleeding [14–16], 
although the incidences of ischemic stroke (IS) is 
obviously lower for low-risk AF patients. There-
fore, investigating the effectiveness of preventing 
IS of monotherapy of ASA or warfarin in low-
stroke-risk AF patients by using a large population-
based database is needed [17]. Based on the above 
mentioned reasons, this study aimed to investigate 
the effectiveness in preventing IS of monotherapy 
of ASA or warfarin in low-risk AF patients by using 
a population-based database, the National Health 
Insurance Research Database (NHIRD), in Taiwan.
Methods
Study database
This study used claims data from Taiwan’s 
National Health Insurance (NHI) program, which 
was launched by the Taiwan government in  March, 
1995 and provided comprehensive health care for 
99.5% of its residents in 2010 [18]. The NHIRD 
contains nationwide information including outpa-
tient, inpatient, dentistry services, prescription 
drugs, and traditional Chinese medicine services. 
The diagnostic and procedure codes are based on 
the International Classification of Diseases, Ninth 
revision, Clinical Modification (ICD-9-CM) and 
Procedure Coding System (ICD-9-PCS). 
Ethics statement
The Institutional Review Board of School 
of Nursing, National Taipei University of Nurs-
ing and Health Sciences approved this study 
(CN-IRB-2011-064). The National Health Research 
Institutes encrypt the personal information to pro-
tect individual information of patients. The National 
Health Insurance Administration guarantees the 
confidentiality of the personal and health informa-
tion of patients.
Study population
An incidence-based patient cohort of newly 
diagnosed AF patients (ICD-9-CM code 427.31) 
who had at least two outpatient visits with primary 
disease of AF and whose CHA2DS2-VASc scores 
were < 2 (= 0 or 1) without a history of stroke 
events (including IS, hemorrhagic stroke [HS], and 
transient ischemic attack [TIA]) were identified 
and retrieved from NHIRD in 2008. This study 
cohort was followed up for up to 2 years (2010) 
to observe if they had an IS onset which was also 
defined by using ICD-9-CM code 430-438 [19]. 
In order to identify real low-risk AF patients, AF 
patients with severe baseline diseases were also 
excluded: cancers, coronary artery disease (CAD, 
including congenital heart defect [CHD], myocar-
dial infarction [MI], and heart failure [HF]), kidney 
failure (including chronic kidney failure [CKD]), 
abnormal renal and liver function as well as periph-
eral artery disease (PAD). Apart from that, based 
on one recently published study [11] which showed 
that combining the use of ASA and warfarin may 
result in unexpected vascular diseases and some 
cardiovascular disorders, therefore, patients who 
used concomitant drugs of both ASA and warfarin 
were also excluded. The enrollment scheme of 
study patients is shown in Figure 1.
Covariate assessment
The covariate variables including sex, age, 
baseline hypertension status, DM status and hy-
perlipidemia status were also taken into account. 
Additionally, to identify the low-stroke-risk AF 
patients, CHA2DS2-VASc score was adopted and 
was defined as: congestive HF, hypertension, age 
(> 65 = 1 point, > 75 = 2 points), DM, previous 
stroke or TIA (2 points), vascular disease (including 
PAD, previous MI, aortic atheroma), and sex (fe-
male gender). In this study, the study cohort were 
all with CHA2DS2-VASc score < 2 (0 or 1), which 
was considered suitable for defining “low-risk” 
for East Asian AF patients [20, 21]. Besides, the 
HAS-BLED [22] score was also calculated based on 
ICD-9-CM code. The HAS-BLED scoring system 
mainly calculates the risk of major bleeding, which 
was defined as intracranial bleeding, bleeding 
requiring hospitalization, a hemoglobin decrease 
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of more than 2 g/dL, or the need for transfusion 
secondary to bleeding.
Statistical analysis
The longitudinal data were analyzed by using 
generalized estimation equations (GEE). GEE is 
a comprehensive extension of generalized linear 
models (GLZM) in that they allow for adjusting 
correlation structure between observations for 
each subject. The strength of GEE is that they do 
not require precise specification of multivariate 
distribution but only of the structure of means or 
logits for each repeated measurement [23]. In this 
study, the GEE for longitudinal binary outcome 
was used (with/without IS) [24]. The modeling 
was as below:
Define the marginal mean and variances of yij 
as mij = E(mij|Xij) and Var(yij) = mij (1 – mij). Then 
the marginal logit link function was used:
logit(mij) = log(           ) = b’Xij
where b is the GEE coefficient vector to be es-
timated. The GEE estimator b of b is obtained 
through estimating the following GEE model:
n
–1
D’ V (y  – m ) = 0
i i i i
i=1
å
where mi = (mi1, ..., mni)’, D’i = dmi/db and Vi is 
the working covariance matrix of yi, which can be 
expressed as Vi = Ai1/2Rwi(g)Ai1/2, where Rwi(g) is 
a working correlation matrix with parameter g, which 
can be estimated from empirical data. In this study, 
a compound symmetry (or called exchangeable) form 
of working correlation matrix was used as follows:
where r was estimated from the data. The odds ratio 
(OR) of IS of AF patients with and without taking 
ASA and warfarin were calculated. The results were 
expressed using ORs with 95% confidence intervals 
(CIs). My Structured Query Language (MySQL) was 
used for extraction, linkage, and processing of data. 
All statistical analyses were performed using IBM 
SPSS statistical software Version 20 (IBM Corp., 
mij
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Excluded:
1. Conrmed stroke diagnoses histories: 
 including ischemic stroke, hemorrhagic
  and transient ischemic attack
2. Baseline severe diseases: including cancers,
  coronary artery disease (including congenital heart
 defect, myocardial infarction, heart failure), kidney 
 failure (including chronic kidney failure, abnormal
 renal and liver function and peripheral artery disease
3. CHA DS -VASc score ≥ 2
2 2
4. Concomitant drug use of acetylsalicylic acid 
 and warfarin
Newly diagnosed with atrial brillation 
who had at least two outpatient visits 
with ICD-9-CM code = 427.31 in 2008
N = 32.362 
Newly diagnosed atrial brillation 
patients with low-stroke-risk in 2008
N = 8.065
Followed up to 2 years to observe 
the onset of ischemic stroke 
till 2010, which was dened 
using ICD-9-CM code = 430–438
Figure 1. Enrollment scheme of this study.
Ÿ
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New York, NY, USA). A two-tailed p < 0.05 was 
considered statistically significant.
Results
This study recruited 8,065 low risk AF pa-
tients aged ≥ 20 years old, who had at least two out-
patient visits with a primary diagnosis of AF, whose 
CHA2DS2-VASc score < 2 (= 0 or 1), without 
a history of baseline events of stroke (including HS, 
IS, and TIA) and without severe baseline diseases 
which include: cancers, CAD (including CHD, MI, 
and HF), kidney failure (including CKD) and PAD 
in 2008. The mean age was 55.95 years old (stand-
ard deviation [SD] = 11.60), 78.7% were male and 
21.3% were female. Among the study cohort, 4.9% 
of patients had hypertension, 1.9% with DM, and 
2.4% with hyperlipidemia. Additionally, 57.7% 
of patients were with CHA2DS2-VASc score = 0 
and 42.3% were with CHA2DS2-VASc score = 1. 
Among the study cohort, 7.4% took ASA and 4.6% 
took warfarin in 2008 (Table 1).
The distribution of HAS-BLED score was: 
89.1% were with 0, 9.5% with 1, and 1.4% with 2. Re-
garding major bleeding events, according to the da-
tabase used in this study, there were no major bleed-
ing events found in this study database (Table 1). 
The incidences of subsequent IS of this study 
cohort were 2.1% in 2009 and 2.4% in 2010. The 
results of the GEE model showed that low-risk AF 
patients who were with hypertension and received 
warfarin were associated with a statistically sig-
nificant 58.4% reduction of IS risk (OR = 0.416, 
p = 0.024, 95% CI 0.194–0.891). Additionally, low-
risk AF patients with hyperlipidemia and received 
warfarin were associated with a statistically sig-
nificant 69.3% reduction in IS risk (OR = 0.307, 
p = 0.044, 95% CI 0.097–0.969) (Table 2).
Discussion
This study used the Taiwan NHIRD, which 
is a large-scale population-based database to in-
vestigate the effectiveness of preventing IS with 
a monotherapy of ASA or warfarin among low-
stroke-risk AF patients. The results of this study 
showed that warfarin can help in preventing IS 
for low-risk AF patients with hypertension and 
hyperlipidemia. This study agreed with related 
published studies which defined low-risk solely 
used CHA2DS2-VASc score [25, 26]. Regarding 
rates of receiving ASA or warfarin, one published 
study, also using Taiwan NHIRD between 2001 to 
2008 showed that the rates of general AF patients 
(including low-, medium- and high-risk), who re-
ceived warfarin, ASA, or no treatment in Taiwan 
was 16%, 62%, and 22% [27]. In comparison with 
the results of the present study, for low-risk AF 
patients, 7.4% had a monotherapy of ASA and 4.6% 
had a monotherapy of warfarin, which were lower 
than the previously mentioned study [27]. In ad-
dition, one published result of a large scale study 
conducted in the United States [9] in a high-risk 
group showed that 38.2% of AF patients receiving 
ASA, and 61.8% receiving warfarin or non-vitamin 
K antagonist oral anticoagulants.
Regarding the use of ASA for low-risk AF 
patients, the results of this study did not show 
a statistically significant effectiveness, which 
agreed with published studies demonstrating that 
ASA had limited or non-significant effectiveness 
for preventing IS in recent years [28, 29]. A ran-
domized clinical trial conducted in Japan showed 
Table 1. Demographic information of study  
cohort in 2008 (n = 8,065).
N %
Age (mean ± SD)       55.95 ± 11.60
Sex:
Female 1,719 21.3
Male 6,346 78.7
Hypertension:
With 396 4.9
Without 7.669 95.1
Diabetes mellitus:
With 155 1.9
Without 7,910 98.1
Hyperlipidemia:
With 193 2.4
Without 7,872 97.6
Acetylsalicylic acid:
Taking 599 7.4
Not taking 7,466 92.6
Warfarin:
Taking 372 4.6
Not taking 7,693 95.4
CHA2DS2-VASc score
0 4,653 57.7
1 3,412 42.3
HAS-BLED score
0 7,187 89.1
1 763 9.5
2 115 1.4
SD — standard deviation
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that low-dose ASA cannot provide significant effec-
tiveness for stroke prevention among low-risk AF 
patients [29]. In 2016, the Taiwan Heart Rhythm 
Society and the Taiwan Society of Cardiology is-
sued Guidelines  for the management of AF in 
Taiwan, which stated that ASA did not benefit in 
stroke prevention in patients with nonvalvular AF, 
dual antiplatelet therapy (DAPT) of ASA and clopi-
dogrel did not benefit in the prevention of stroke in 
patients with nonvalvular AF, unless under other 
therapeutic indications, such as in patients with 
acute coronary syndrome and receiving stenting 
therapy [30]. The results of the present study may 
support the management guideline. Additionally, 
one expert opinion proposed that ASA may be 
over-prescribed among AF patients [31], probably 
due to the low price of ASA compared with war-
farin [32]. Therefore, although ASA was widely 
prescribed, the results of this study showed that 
ASA did not benefit in preventing IS for low-risk 
AF patients. 
In addition, it is worth noting that low-risk 
newly diagnosed AF patients still may have a risk 
of IS onset in the following 2 years (2.1~2.4% as 
shown in the present study), which was similar 
with one large scale study conducted in European 
countries which showed that IS incidence rates 
were 2.1, 3.0, and 4.2% for paroxysmal, persis-
tent, and permanent AF, respectively [33]. In 
summary, results of this study can provide some 
clinical implications: first, intensive monitoring of 
stroke events (including HS, IS and TIA), which is 
strongly suggested and some associated symptoms, 
for example, FAST [34]: face drooping, arm weak-
ness, speech difficulty and time to call emergency 
help (ex. 911) and low-risk AF patients should be 
carefully reminded of this. Second, warfarin can 
help in preventing IS for low-risk AF patients with 
hypertension and hyperlipidemia.
Limitations of the study
This study had some limitations. First, the 
NHIRD did not provide information of potential 
confounders including smoking, alcohol drinking, 
life style, diet and  other factors, which are as-
sociated with the risk of IS. Second, AF patients 
can buy over-the-counter ASA in drug stores, 
which were not recorded in NHIRD, so that some 
AF patients may use warfarin concurrently with 
ASA, which will result in an underestimate for 
the number of patients using ASA. One published 
study proposed that combining the use of ASA and 
warfarin was inappropriate [11], it is believed that 
a number of AF patients may concurrently use both 
Table 2. The results of generalized estimation equations. 
Parameter OR 95% CI for OR
Lower Upper P
Main effects:
(Intercept) 0.003 0.002 0.005 < 0.001***
Sex (male vs. female) 0.972 0.687 1.378 0.875
Age 1.010 0.998 1.023 0.106
Year 2.697 2.403 3.027 < 0.001***
ASA 2.377 1.427 3.961 0.001**
WARFARIN 7.345 4.419 12.208 < 0.001***
Hypertension 2.200 1.409 3.436 0.001**
DM 1.760 0.694 4.464 0.234
Hyperlipidemia 3.929 1.516 10.182 0.005**
Interaction effects:
ASA × Hypertension 1.540 0.737 3.218 0.251
ASA × DM 1.983 0.406 9.693 0.398
ASA × Hyperlipidemia 1.382 0.550 3.469 0.491
WARFARIN × Hypertension 0.416 0.194 0.891 0.024*
WARFARIN × DM 0.711 0.119 4.238 0.708
WARFARIN × Hyperlipidemia 0.307 0.097 0.969 0.044*
ASA — acetylsalicylic acid; CI — confidence interval; DM — diabetes mellitus; OR — odds ratio; *p < 0.05; **p < 0.01; ***p < 0.001
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ASA and warfarin, which could not be identified in 
NHIRD. Third, due to the nature of the study da-
tabase, it was an outpatient claims database which 
provided only drug prescriptions without dosage 
information, therefore the dose effect could not 
be analyzed and was regarded as another study 
limitation. Fourth, published studies have shown 
that poor adherence to anticoagulation guidelines 
in patients with AF [35–37]. Although we may code 
one AF patient with the prescription of ASA or 
warfarin from the claims database, it could not be 
verified that the information of drug compliance of 
the recruited AF patients in this study was carried 
out. Lastly, although there were no major bleeding 
events found in this study database, there were 
probably minor bleeding events which were not 
recorded in NHIRD, which was also regarded as 
a study limitation.
Conclusions
The present study used a large scale popu-
lation-based database which showed that mono-
therapy of warfarin was suggested in prescribing 
for the prevention of IS in low-stroke-risk AF 
patients, especially for low-risk AF patients with 
hypertension and hyperlipidemia. 
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